Annual reports filed by certain Canadian issuers pursuant to Section 15(d) and Rule 15d-4

Segment disclosures

v3.19.3.a.u2
Segment disclosures
12 Months Ended
Dec. 31, 2019
Segment disclosures [Abstract]  
Segment disclosures
Segment disclosures
The Company’s operations comprise a single reporting segment engaged in the research, development and commercialization of therapeutic drugs. As the operations comprise a single reporting segment, amounts disclosed in the consolidated financial statements represent those of the single reporting unit. In addition, all of the Company’s long-lived assets are located in Canada.
The following geographic information reflects revenue based on customer location.

2019
$

 
2018
$

Revenue

 

United States
200

 
345

China
118

 
118


318

 
463